Lilly maintains deal streak with $1.2B pact for Hanmi’s GLP-2 candidate

Lilly Licenses Hanmi's GLP-2 Candidate for Short Bowel Syndrome

Eli Lilly has entered into a licensing agreement with South Korea’s Hanmi Pharm for sonefpeglutide, a mid-stage GLP-2 agonist being developed for short bowel syndrome. The deal is valued at up to $1.2 billion, including an upfront payment of $75 million and subsequent milestone payments. Under the agreement, Lilly secures exclusive global rights to manufacture and sell the therapy, with the exception of Korea. Hanmi will complete the ongoing Phase 2 study, while Lilly plans to explore additional clinical trials, further expanding its presence in the metabolic and gastrointestinal therapeutic areas.

• Eli Lilly's agreement with Hanmi Pharm is structured with an upfront payment of $75 million, contributing to a potential total deal value of $1.2 billion upon the achievement of specific development and commercial milestones. Lilly gains exclusive rights to manufacture and commercialize sonefpeglutide worldwide, excluding Korea, where Hanmi retains its rights. Hanmi is responsible for completing the current Phase 2 study for short bowel syndrome, after which Lilly intends to pursue further clinical development based on existing data.
• Sonefpeglutide is a GLP-2 agonist designed to treat short bowel syndrome, a rare condition characterized by impaired nutrient absorption due to a shortened or damaged small intestine. The drug's mechanism aims to promote intestinal growth, reduce inflammation, and support the regeneration of intestinal mucosa. This candidate enters a market where Takeda's Gattex, another GLP-2, is already approved, and follows Zealand Pharma's glepaglutide, which faced an FDA rejection, highlighting the competitive landscape for this therapeutic class.
• This licensing deal signifies Eli Lilly's continued strategic expansion into gastrointestinal indications, complementing its dominant position in the GLP-1 weight loss market with blockbusters like Zepbound and Mounjaro. The company has demonstrated an aggressive R&D-focused growth mindset through a series of recent acquisitions and partnerships, including multiple vaccine and oncology deals totaling billions of dollars, underscoring its commitment to diversifying its pipeline and bringing new treatments to market.

The Persistent Challenges in Managing Short Bowel Syndrome

Short bowel syndrome presents multiple complex management challenges that significantly impact both patients and healthcare systems. Current treatment approaches face substantial limitations in addressing the multifaceted nature of this condition, from immediate postoperative complications to long-term quality of life concerns.

• Significant Quality of Life Burden: Patients with SBS experience markedly reduced quality of life compared to the general population, particularly affecting physical functioning and psychological wellbeing, while requiring lengthy parenteral support infusions and GLP-2 analog injections that further compromise daily functioning.

• Limited Evidence Base: There is a notable scarcity of large-sample quantitative studies examining quality of life determinants, with existing literature on caregiver impacts being particularly deficient, hindering evidence-based treatment optimization.

• Insufficient Pediatric Treatment Data: Limited clinical data exists for pediatric patients, especially those weighing less than 10 kg, creating challenges in developing appropriate dosing regimens and treatment protocols for this vulnerable population.

• Complex Complication Management: Patients frequently develop serious complications including cholestasis, renal insufficiency, and metabolic bone disease, requiring sophisticated prevention and management strategies that add complexity to treatment regimens.

• High Treatment Failure Risk: Short bowel syndrome represents the only underlying condition significantly associated with treatment failure, with specific interventions like metronidazole conferring a 5-fold increased risk of recurrence in pediatric CDI cases.

• Early Postoperative Management Complexity: The immediate postoperative period involves managing considerable malabsorption, vitamin and trace element deficiencies, total parenteral nutrition complications, and recurrent infections, with recovery potentially taking 1-3 years.

Lilly's Bold Move Reshapes the SBS Treatment Landscape

The landscape for treating short bowel syndrome (SBS), a severe condition often requiring lifelong parenteral support (PS), is poised for potential evolution with Eli Lilly's strategic licensing of sonefpeglutide. Current treatment paradigms for SBS patients dependent on PS largely revolve around teduglutide, a glucagon-like peptide-2 (GLP-2) analogue that has demonstrated significant benefits in promoting intestinal adaptation and reducing PS needs. However, despite its efficacy, teduglutide is a high-cost therapy, and ongoing research continues to explore ways to 'break the therapeutic ceiling' of intestinal rehabilitation, including the development of longer-acting GLP-2 analogues.

Lilly's substantial investment in sonefpeglutide signals a clear intent to enter and potentially reshape this specialized market. For Lilly, this move diversifies its metabolic and gastrointestinal portfolio, leveraging a well-understood mechanism of action in an orphan disease area. For Hanmi Pharm, the agreement validates its research efforts and provides significant funding for future innovation. However, the path forward is not without challenges. Sonefpeglutide will need to demonstrate compelling differentiation against the established teduglutide, whether through superior efficacy, an improved safety profile, or enhanced patient convenience, such as less frequent dosing. The class of GLP-2 agonists is associated with known adverse events, including gastrointestinal symptoms, fluid balance issues, and a theoretical concern regarding the progression of intestinal neoplasms, which will require careful monitoring and clear communication during development. Furthermore, the economic burden of SBS therapies is a critical consideration, and sonefpeglutide's eventual pricing and cost-effectiveness will be paramount for broad adoption. This development underscores the ongoing commitment within pharma to address high unmet needs in rare diseases, while also highlighting the competitive and clinical hurdles new entrants must overcome.